MW03

MW03 is a preclinical-stage small interfering RNA (siRNA) therapeutic candidate being developed by Moonwalk Biosciences for the treatment of obesity. The program is designed to modulate adipogenesis and the differentiation of adipose tissue, leveraging Moonwalk's epigenetic discovery platform to target the underlying biological processes of fat cell formation. By regulating the maturation and function of adipocytes, MW03 aims to address metabolic dysfunction and energy homeostasis in patients with obesity. As of 2024, the asset is in the preclinical phase of development and is part of a broader pipeline of adipose-targeted epigenetic medicines.